Dr. Douglas previously served as Senior Vice President of Corporate Development at Genzyme

MaxCyte, the global cell-based medicines and technology company, announces that 30-year life sciences industry veteran Richard Douglas, Ph.D., has been appointed to the Company’s Board of Directors as an Independent Non-Executive Director.

Dr. Douglas formerly served as the Senior Vice President of Corporate Development and Corporate Officer at Genzyme Corporation from 1989 until Genzyme was acquired by Sanofi in 2011. During this period, Dr.Douglas led numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. He had previously served in science and corporate development capacities at Integrated Genetics prior to its acquisition by Genzyme.He currently serves as an Advisor to RedSky Partners, a Biotechnology-focused advisory firm.

Dr. Douglas received a Ph.D. in Biochemistry from the University of California, Berkeley, and was a Post-Doctoral Fellow at California Institute of Technology in Leroy Hood’s laboratory. He has a degree in Chemistry from the University of Michigan, where he now serves as chair of the National Advisory Board for the Office of Technology Transfer and also on two translational research oversight committees for the University’s Medical School.

“Richard’s wealth of expertise in business and corporate development and his deep life sciences industry experiencewill bring invaluable perspective tothe MaxCyte Board,” said MaxCyte President & CEO Doug Doerfler. “We are extremely pleased to have Richard as part of our organization as we further our enablement of new medicines in the areas of gene editing and immuno-oncology, and move our first product candidate from our CARMA therapeutic platform into the clinic.”

“I have followed MaxCyte’s progress closely over the previous years and I believe its technology is truly revolutionary,” said Dr. Douglas. “With the first CARMA therapy due to enter the clinic later this year, I am delighted to join MaxCyte at this exciting time in its development. I look forward to working closely with the Board and management team in bringing the next generation of treatments to patients.”

About MaxCyte

MaxCyte is a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering enabling technology to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery technology, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This technology allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering enabling technology is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumours where existing CAR-T approaches face significant challenges. For more information, visit http://www.maxcyte.com/.